Announcements Trials
Browse Landscape

Phase

Phase 2 76Phase 1 29Phase 1/2 26Phase 3 7Phase 4 3Phase NA 2Phase EARLY_PHASE1 2

Status

Terminated 2Completed 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 3Genitourinary 2Other hematologic neoplasm 1

Conditions

Melanoma 3Skin Neoplasms 2Neoplasm Metastasis 1Carcinoma, Renal Cell 1

Interventions

Imiquimod 15Aminolevulinic Acid 8Fluorouracil 6Diclofenac 63-ingenyl angelate 6Nivolumab 5Cryotherapy 5tirbanibulin 4methyl 5-aminolevulinate 4Sirolimus 4denileukin diftitox 3aldesleukin 3Photochemotherapy 3Ipilimumab 3Blood Specimen Collection 3relatlimab 2Vemurafenib 2Tacrolimus 2Prednisone 2Ointments 2Methotrexate 2Immune Checkpoint Inhibitors 2HhAntag691 2Gels 2Cyclosporine 2Cryosurgery 2trametinib 1technetium-diethylenetriaminepentaacetic acid-mannosyl-dextran 1technetium Tc 99m nanocolloid 1sargramostim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 4 × aldesleukin × Dermatologic × Clear all
NCT01856023 2023-12-05

PROCLIVITY02

Clinigen, Inc.

Phase 4 Terminated
29 enrolled 9 charts
Dermatologic

Melanoma, Neoplasm Metastasis, Skin Neoplasms

NCT00414765 2021-06-08

Aldesleukin in Participants With Metastatic Renal Cell Carcinoma or Metastatic Melanoma

Novartis

Phase 4 Completed
26 enrolled 7 charts
DermatologicGenitourinary

Carcinoma, Renal Cell, Melanoma

NCT01683188 2021-02-01

PROCLIVITY01

Clinigen, Inc.

Phase 4 Terminated
53 enrolled
Dermatologic

Melanoma, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡